Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Cantor Fitzgerald Initiates Coverage On KemPharm with Overweight Rating, Announces Price Target of $20

Author: Benzinga Newsdesk | November 17, 2022 07:17am
Cantor Fitzgerald analyst Louis Chen initiates coverage on KemPharm (NASDAQ:KMPH) with a Overweight rating and announces Price Target of $20.

Posted In: KMPH

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist